Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
2.

Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.

Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Pregja S, Osman K, Tsai WY, Landau H, Sanchorawala V.

Amyloid. 2019;26(sup1):113-114. doi: 10.1080/13506129.2019.1583200. No abstract available.

PMID:
31343313
3.

Use of novel therapies in the treatment of light chain amyloidosis.

Varga C, Titus SE, Toskic D, Comenzo RL.

Blood Rev. 2019 Sep;37:100581. doi: 10.1016/j.blre.2019.05.005. Epub 2019 May 22. Review.

PMID:
31167719
4.

Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms.

Xingguang Lee L, Zhou P, Varga C, Fogaren T, Ho K, Ma X, Warner M, Toskic D, Kugelmass A, Comenzo RL.

Amyloid. 2019 Jun;26(2):101-102. doi: 10.1080/13506129.2019.1600498. Epub 2019 May 23. No abstract available.

PMID:
31119957
5.

A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases.

Ma X, Zhou P, Kugelmass A, Toskic D, Warner M, Lee L, Fogaren T, Godara A, Wang M, Li Y, Yang L, Xu Q, Comenzo RL.

Gene Ther. 2019 May;26(5):187-197. doi: 10.1038/s41434-019-0070-y. Epub 2019 Mar 29.

PMID:
30926963
6.

Stigmata of amyloidosis; external manifestations of internal disease.

Chaulagain CP, Comenzo RL.

Br J Haematol. 2019 Jul;186(1):10. doi: 10.1111/bjh.15885. Epub 2019 Mar 27. No abstract available.

PMID:
30916377
7.

A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis.

Fu J, Lee LX, Zhou P, Fogaren T, Varga C, Comenzo RL.

Am J Case Rep. 2019 Jan 11;20:43-47. doi: 10.12659/AJCR.912282.

8.

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth.

Ma X, Wong SW, Zhou P, Chaulagain CP, Doshi P, Klein AK, Sprague K, Kugelmass A, Toskic D, Warner M, Miller KB, Lee L, Varga C, Comenzo RL.

Exp Hematol Oncol. 2018 Oct 16;7:27. doi: 10.1186/s40164-018-0119-4. eCollection 2018.

9.

Beyond NEOD001 for systemic light-chain amyloidosis.

Varga C, Lentzsch S, Comenzo RL.

Blood. 2018 Nov 1;132(18):1992-1993. doi: 10.1182/blood-2018-07-865857. Epub 2018 Sep 21. No abstract available.

PMID:
30242086
10.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.

Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e493-e499. doi: 10.1016/j.clml.2018.07.292. Epub 2018 Jul 25.

11.

High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review.

Varga C, Comenzo RL.

Bone Marrow Transplant. 2019 Apr;54(4):508-518. doi: 10.1038/s41409-018-0284-4. Epub 2018 Aug 8.

PMID:
30089901
12.

Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.

Nguyen VP, Rosenberg A, Mendelson LM, Comenzo RL, Varga C, Sanchorawala V.

Amyloid. 2018 Sep;25(3):156-159. doi: 10.1080/13506129.2018.1490261. Epub 2018 Jul 21.

PMID:
30032640
13.

Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center.

Wong SW, Toskic D, Warner M, Varga C, Moreno-Koehler A, Fein D, Fogaren T, Lee L, Oliver CM, Guthrie SD, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):759-766. doi: 10.1016/j.clml.2017.06.004. Epub 2017 Jun 17.

PMID:
28689003
14.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

PMID:
28550039
15.

Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy.

Wong SW, Larivee D, Warner M, Sprague KA, Fogaren T, Comenzo RL.

Bone Marrow Transplant. 2017 Jun;52(6):936-937. doi: 10.1038/bmt.2017.47. Epub 2017 Apr 10. No abstract available.

PMID:
28394371
16.

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.

Landau H, Smith M, Landry C, Chou JF, Devlin SM, Hassoun H, Bello C, Giralt S, Comenzo RL.

Leukemia. 2017 Jan;31(1):136-142. doi: 10.1038/leu.2016.229. Epub 2016 Aug 18.

17.

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.

Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL.

Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15. Review.

18.

siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases.

Ma X, Zhou P, Wong SW, Warner M, Chaulagain C, Comenzo RL.

Gene Ther. 2016 Oct;23(10):727-733. doi: 10.1038/gt.2016.50. Epub 2016 Jun 20.

PMID:
27383253
19.

Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.

Weiss BM, Wong SW, Comenzo RL.

Blood. 2016 May 12;127(19):2275-80. doi: 10.1182/blood-2015-11-681650. Epub 2016 Feb 23. Review.

PMID:
26907632
20.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M.

J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.

21.

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium.

Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G.

Adv Ther. 2015 Oct;32(10):920-8. doi: 10.1007/s12325-015-0250-0. Epub 2015 Oct 23.

22.

CD38 Monoclonal Antibody Therapies for Multiple Myeloma.

Wong SW, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):635-45. doi: 10.1016/j.clml.2015.07.642. Epub 2015 Aug 5. Review.

PMID:
26443328
23.

Out, Out--Making Amyloid's Candle Briefer.

Comenzo RL.

N Engl J Med. 2015 Sep 17;373(12):1167-9. doi: 10.1056/NEJMe1508746. No abstract available.

PMID:
26376140
24.

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P.

J Clin Oncol. 2015 Nov 10;33(32):3741-9. doi: 10.1200/JCO.2015.62.4015. Epub 2015 Sep 14.

25.

How we treat systemic light-chain amyloidosis.

Chaulagain CP, Comenzo RL.

Clin Adv Hematol Oncol. 2015 May;13(5):315-24. Review.

PMID:
26352777
26.

Three-dimensional Speckle Tracking Echocardiography in Light Chain Cardiac Amyloidosis: Examination of Left and Right Ventricular Myocardial Mechanics Parameters.

Urbano-Moral JA, Gangadharamurthy D, Comenzo RL, Pandian NG, Patel AR.

Rev Esp Cardiol (Engl Ed). 2015 Aug;68(8):657-64. doi: 10.1016/j.rec.2015.01.009. Epub 2015 Jun 17.

PMID:
26092748
27.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8.

28.

Plasma cell neoplasms, their precursor States, and their prediction of organ damage.

Comenzo RL.

J Clin Oncol. 2014 Sep 1;32(25):2679-82. doi: 10.1200/JCO.2014.56.2892. Epub 2014 Jul 14. No abstract available.

PMID:
25024079
29.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):380-8. doi: 10.1016/j.clml.2014.03.005. Epub 2014 Jun 11.

PMID:
25023616
30.

Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis.

Kaul E, Shah G, Chaulagain C, Comenzo RL.

Bone Marrow Transplant. 2014 Sep;49(9):1233. doi: 10.1038/bmt.2014.117. Epub 2014 Jun 16. No abstract available.

PMID:
24933207
31.

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP.

Haematologica. 2014 Sep;99(9):1479-85. doi: 10.3324/haematol.2014.104109. Epub 2014 May 23.

32.

One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress.

Zhou P, Ma X, Iyer L, Chaulagain C, Comenzo RL.

Blood. 2014 May 29;123(22):3440-51. doi: 10.1182/blood-2013-10-535187. Epub 2014 Apr 10.

PMID:
24723680
33.

LECT2 makes the amyloid list.

Comenzo RL.

Blood. 2014 Mar 6;123(10):1436-7. doi: 10.1182/blood-2014-01-549758.

PMID:
24627547
34.

Immunoglobulin light chain amyloidosis.

Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA.

Expert Rev Hematol. 2014 Feb;7(1):143-56. doi: 10.1586/17474086.2014.858594. Epub 2013 Dec 18. Review.

PMID:
24350907
35.

Twists and turns of determining amyloid type and amyloid-related organ damage: discordance and clinical skepticism in the era of proteomic typing.

Kaul E, Pilichowska M, Vullaganti M, Madan N, Comenzo RL.

Amyloid. 2014 Mar;21(1):62-5. doi: 10.3109/13506129.2013.856779. Epub 2013 Nov 20.

PMID:
24256111
36.

New insights and modern treatment of AL amyloidosis.

Chaulagain CP, Comenzo RL.

Curr Hematol Malig Rep. 2013 Dec;8(4):291-8. doi: 10.1007/s11899-013-0175-0. Review.

PMID:
24026941
37.

The challenge of systemic immunoglobulin light-chain amyloidosis (Al).

Palladini G, Comenzo RL.

Subcell Biochem. 2012;65:609-42. doi: 10.1007/978-94-007-5416-4_22. Review.

PMID:
23225018
38.

Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis.

Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C, Bello C, Hoover E, Riedel E, Giralt S, Comenzo RL.

Leukemia. 2013 Apr;27(4):823-8. doi: 10.1038/leu.2012.274. Epub 2012 Sep 27.

PMID:
23014566
39.

Cancer-testis antigen expression and immunogenicity in AL amyloidosis.

Rosenzweig MA, Landau H, Seldin D, O'Hara C, Girnius S, Hanson N, Frosina D, Sedrak C, Arcila M, Comenzo RL, Giralt S, Gnjatic S, Jungbluth AA, Koehne G.

Blood Cancer J. 2012 Sep 14;2:e90. doi: 10.1038/bcj.2012.32.

40.

Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis.

Apridonidze T, Steingart RM, Comenzo RL, Hoffman J, Goldsmith Y, Bella JN, Landau H, Liu JE.

Am J Cardiol. 2012 Oct 15;110(8):1180-4. doi: 10.1016/j.amjcard.2012.05.061. Epub 2012 Jul 6.

PMID:
22770934
41.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A.

Clin Cancer Res. 2012 Sep 1;18(17):4830-40. Epub 2012 Jul 3.

42.

Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions.

Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N, Van Etten RA, McKenna DH.

Transfusion. 2013 Feb;53(2):412-8; quiz 411. doi: 10.1111/j.1537-2995.2012.03764.x. Epub 2012 Jun 28.

43.

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.

Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK.

Mol Cancer Ther. 2012 Aug;11(8):1781-8. doi: 10.1158/1535-7163.MCT-11-0949. Epub 2012 May 31.

44.

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G.

Leukemia. 2012 Nov;26(11):2317-25. doi: 10.1038/leu.2012.100. Epub 2012 Apr 5. Review.

PMID:
22475872
45.

Amyloid diseases of the heart: current and future therapies.

Dubrey SW, Comenzo RL.

QJM. 2012 Jul;105(7):617-31. doi: 10.1093/qjmed/hcr259. Epub 2012 Jan 5. Review.

PMID:
22223674
46.

Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.

Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL.

Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):49-58. doi: 10.1016/j.clml.2011.09.217. Epub 2011 Nov 18.

PMID:
22100494
47.

Who knows how to treat systemic light chain amyloidosis?

Comenzo RL.

Oncology (Williston Park). 2011 Jun;25(7):626, 628-9, 632-3. Review. No abstract available.

48.

Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.

Landau H, Hassoun H, Bello C, Hoover E, Riedel ER, Nimer SD, Comenzo RL.

Amyloid. 2011 Jun;18 Suppl 1:135-6. doi: 10.3109/13506129.2011.574354050. No abstract available. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:136.

PMID:
21838462
49.

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.

Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL.

Leuk Lymphoma. 2012 Feb;53(2):275-81. doi: 10.3109/10428194.2011.606943. Epub 2011 Sep 23.

PMID:
21824051
50.

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.

Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, Van De Velde H, Mortimer S, Cakana A, Comenzo RL; Velcade Can2007 Study Group.

QJM. 2011 Nov;104(11):957-70. doi: 10.1093/qjmed/hcr105. Epub 2011 Jul 13.

PMID:
21752867

Supplemental Content

Loading ...
Support Center